Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Zonisamide for Bipolar Disorder, Mania or Mixed States by Deborah Dauphinais
1
x
$
30.00
View Cart
Checkout
Home
Michael E. Thase, MD: Editor’s Letter
Michael E. Thase, MD: Editor’s Letter
$
0.00
Michael E. Thase, MD: Editor's Letter quantity
Add to cart
Want a discount? Become a member by purchasing
Psychopharmacology Bulletin Subscription - Individual
!
Categories:
Psychopharmacology Bulletin
,
VOL 40 No. 3 Articles
Tags:
editors-letter
,
invited-commentary
,
michael-e-thase
,
negative-and-failed-clinical-trial-reports
Description
Description
Michael E. Thase, MD
EDITOR’S LETTER
T
WO
N
EW
S
ECTIONS
O
FFER
F
URTHER
C
HECKS AND
B
ALANCES
: N
EGATIVE AND
F
AILED
C
LINICAL
T
RIAL
R
EPORTS AND
I
NVITED
C
OMMENTARY
Michael E. Thase, MD
Related products
Duloxetine for the Treatment of Major Depressive Disorder
$
30.00
Add to cart
Details
Ripu D. Jindal, MD: Effects of Tranylcypromine on the Sleep of Patients with Anergic Bipolar Depression
$
30.00
Add to cart
Details
The Next Step Forward: A Move Toward Evidence, and Away From Fear of the Industry
$
0.00
Add to cart
Details
A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors
$
30.00
Add to cart
Details
Page load link
Go to Top
Michael E. Thase, MD: Editor’s Letter
$0.00
Description
Michael E. Thase, MD
EDITOR’S LETTER
TWO NEW SECTIONS OFFER FURTHER CHECKS AND BALANCES: NEGATIVE AND FAILED CLINICAL TRIAL REPORTS AND INVITED COMMENTARY
Michael E. Thase, MD
Related products
Duloxetine for the Treatment of Major Depressive Disorder
Ripu D. Jindal, MD: Effects of Tranylcypromine on the Sleep of Patients with Anergic Bipolar Depression
The Next Step Forward: A Move Toward Evidence, and Away From Fear of the Industry
A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors